Therapeutic Delivery – News and Features

Findings describe how natural nanoparticles can be adapted to fight cancer.

The patent covers the manufacture of multifunctional nano- and micron-sized capsules.

Initiative will bring together industry, government and academic experts to drive nanobiology innovation.

Alcon and Dharmacon will select and prioritise disease-related gene targets.

Capsulution will receive funding of EUR 600,000 over a period of 3 years.

The studies aim at increasing the bioavailability of several new chemical entities in the human body.

NCL will characterize DNT's STARBURST™ dendrimers as macromolecular dendrimer-based MRI contrast agents.

The research, published in Cancer Research, represents a significant advance in the development of systemic RNAi therapeutics.

First year awards totaling $26.3 million will help establish seven Centers of Cancer Nanotechnology Excellence.

The agreement provides Angiotech with immediate access to CombinatoRx's combination pharmaceutical compounds.